NCT06925685
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
Enrolling by Invitation
Not specifiedAll AgesObservationalAllogene Therapeutics
~50 participants
Updated 2025-04-13 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of delayed adverse events potentially related to allogeneic CAR T-cell product and allogeneic CAR T-cell product-related SAEs
Measured over Up to 15 years post treatment with allogeneic CAR T-cell product
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesNew York1
Study leadership
- Allogene Study Director · STUDY_DIRECTOR · Allogene Therapeutics, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study
Exclusion
Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor
What this trial measures
- Incidence of delayed adverse events potentially related to allogeneic CAR T-cell product and allogeneic CAR T-cell product-related SAEsUp to 15 years post treatment with allogeneic CAR T-cell product
- Overall survival (OS)Up to 15 years post treatment with allogeneic CAR T cell product
- Presence of replication competent lentivirus (RCL) in bloodUp to 15 years post treatment with allogeneic CAR T cell product